Astellas Pharma Inc - Company Profile
Powered by 
All the data and insights you need on Astellas Pharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Astellas Pharma Inc Strategy Report
- Understand Astellas Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.
Headquarters
Japan
Address
2-5-1, Nihombashihon-Cho, Chuo-Ku, Tokyo, 103-8411
Website
www.astellas.com
Telephone
81 3 32443000
No of Employees
14,484
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4503 (TYO)
Revenue (2022)
$11.2B
17.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-20.4%
(2022 vs 2021)
Market Cap*
$18.6B
Net Profit Margin (2022)
XYZ
-32.1%
(2022 vs 2021)
* As of and is in US$
Astellas Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Xtandi- Treatment of Prostate Cancer |
| Xospata- Acute Myeloid Leukemia |
| Padcev- Metastatic Urothelial Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered into an agreement with CytomX Therapeutics for an additional conditionally activated TCB programs. |
| 2024 | Regulatory Approval | In March, Astellas Pharma US, Inc. received approval from the U.S. Food and Drug Administration for CRESEMBA (isavuconazonium sulfate) to treat invasive aspergillosis and invasive mucormycosis in pediatric patients. |
| 2024 | Regulatory Approval | In March, the company received approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive gastric cancer. |
Competitor Comparison
| Key Parameters | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Eisai Co Ltd | Kyowa Kirin Co Ltd | Taisho Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Bunkyo-Ku | Chiyoda-Ku | Toshima-Ku |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 14,484 | 17,435 | 11,076 | 5,974 | 8,784 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenji Yasukawa | Chairman | Executive Board | 2023 | - |
| Naoki Okamura | Chief Executive Officer; President; Director | Executive Board | 2023 | - |
| Atsushi Kitamura | Chief Financial Officer | Senior Management | 2023 | - |
| Adam Pearson | Chief Strategy Officer | Senior Management | 2023 | - |
| Katsuyoshi Sugita | Chief Ethics and Compliance Officer; Executive Vice President; Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward